Elanco Animal Health (NYSE:ELAN) Issues Earnings Results

Key Points

• Elanco Animal Health reported earnings of $0.26 per share for the quarter, exceeding analysts' expectations of $0.20, and achieved revenues of $1.24 billion, also surpassing the predicted $1.19 billion.
• The company has updated its Q3 2025 guidance to a projected EPS range of 0.120-0.160 and FY 2025 guidance to 0.850-0.91 EPS.
• Elanco's stock saw a recent upward adjustment in ratings from several research firms, with most analysts now giving it a consensus rating of "Moderate Buy" and an average price target of $16.17.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.06, Zacks reports. The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.30 EPS. Elanco Animal Health updated its Q3 2025 guidance to 0.120-0.160 EPS and its FY 2025 guidance to 0.850-0.91 EPS.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $16.39 on Friday. The stock has a market capitalization of $8.14 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.71 and a beta of 1.66. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.71 and a quick ratio of 1.46. The firm's 50 day simple moving average is $14.26 and its 200-day simple moving average is $12.05. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $16.70.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Empowered Funds LLC lifted its holdings in Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock valued at $166,000 after purchasing an additional 4,121 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Elanco Animal Health during the 1st quarter valued at about $2,065,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after purchasing an additional 76,408 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ELAN. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. UBS Group upped their price target on shares of Elanco Animal Health from $17.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Leerink Partnrs upgraded Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price objective for the company in a research note on Thursday, July 17th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.